

# Beyond thrombosis: Anti-Î²2GPI domain 1 antibodies id anti-phospholipid syndrome

Journal of Autoimmunity

90, 76-83

DOI: [10.1016/j.jaut.2018.02.002](https://doi.org/10.1016/j.jaut.2018.02.002)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. <i>Journal of Autoimmunity</i> , 2018, 90, 1-27.	6.5	60
2	Obstetric antiphospholipid syndrome. <i>Lupus Science and Medicine</i> , 2018, 5, e000197.	2.7	42
3	The clinical value of assays detecting antibodies against domain I of $\beta$ 2-glycoprotein I in the antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018, 17, 1210-1218.	5.8	27
4	Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2018, 9, 1388.	4.8	51
5	Obstetric Anti-phospholipid Syndrome: State of the Art. <i>Current Rheumatology Reports</i> , 2018, 20, 59.	4.7	12
6	Tolerogenic $\beta$ 2-glycoprotein I DNA vaccine and FK506 as an adjuvant attenuates experimental obstetric antiphospholipid syndrome. <i>PLoS ONE</i> , 2018, 13, e0198821.	2.5	4
7	Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 433-440.	8.0	95
8	Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. <i>Frontiers in Immunology</i> , 2019, 10, 1948.	4.8	33
9	Anti-domain 1 of beta2-glycoprotein I aids risk stratification in lupus anticoagulant-positive patients. <i>Clinical and Experimental Medicine</i> , 2019, 19, 339-345.	3.6	6
10	Structural and functional characterization of $\beta$ 2-glycoprotein I domain 1 in anti-melanoma cell migration. <i>Cancer Science</i> , 2019, 110, 1974-1986.	3.9	2
11	Challenges and Advances in SLE Autoantibody Detection and Interpretation. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 147-167.	1.4	9
12	Oral administration of Domain-I of beta-2glycoprotein-I induces immunological tolerance in experimental murine antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2019, 99, 98-103.	6.5	12
13	New insight into antiphospholipid syndrome: antibodies to $\beta$ 2glycoprotein I-domain 5 fail to induce thrombi in rats. <i>Haematologica</i> , 2019, 104, 819-826.	3.5	40
14	Management of pregnant women with antiphospholipid antibodies. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 347-358.	3.0	18
15	Management of antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 155-161.	0.9	85
16	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. <i>Blood Reviews</i> , 2020, 39, 100610.	5.7	85
17	Anti- $\beta$ 2GPI domain 1 antibodies stratify high risk of thrombosis and late pregnancy morbidity in a large cohort of Chinese patients with antiphospholipid syndrome. <i>Thrombosis Research</i> , 2020, 185, 142-149.	1.7	19
18	Detection of anti-domain I antibodies by chemiluminescence enables the identification of high-risk antiphospholipid syndrome patients: A multicenter multiplatform study. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 463-478.	3.8	20

#	ARTICLE	IF	CITATIONS
19	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , 2020, 11, 584241.	4.8	137
20	16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. <i>Lupus</i> , 2020, 29, 1601-1615.	1.6	27
21	The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low risk for chromosomal abnormalities. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2921-2928.	3.8	7
22	Prevention of Pregnancy Complications in Antiphospholipid Syndrome. <i>Hamostaseologie</i> , 2020, 40, 174-183.	1.9	6
23	Elevated IgA antiphospholipid antibodies in healthy pregnant women in Sudan but not Sweden, without corresponding increase in IgA anti- $\beta_2$ glycoprotein I domain 1 antibodies. <i>Lupus</i> , 2020, 29, 463-473.	1.6	6
24	Anti-domain 1 $\beta_2$ glycoprotein antibodies increase expression of tissue factor on monocytes and activate NK Cells and CD8+ cells in vitro. <i>Autoimmunity Highlights</i> , 2020, 11, 5.	3.9	6
25	Non-criteria antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 33.	3.5	49
27	Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis. <i>Journal of Nephrology</i> , 2020, 33, 757-762.	2.0	6
28	Anti-phospholipid antibodies and reproductive failures. <i>American Journal of Reproductive Immunology</i> , 2021, 85, e13258.	1.2	13
29	Antibodies and diagnostic tests in antiphospholipid syndrome. , 2021, , 565-574.		1
30	Challenges and Advances in SLE Autoantibody Detection and Interpretation. , 2021, , 67-91.		1
31	Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding. <i>Scientific Reports</i> , 2021, 11, 4542.	3.3	3
32	B cells in primary antiphospholipid syndrome: Review and remaining challenges. <i>Autoimmunity Reviews</i> , 2021, 20, 102798.	5.8	10
33	Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One. <i>Frontiers in Immunology</i> , 2021, 12, 726820.	4.8	21
34	In vivo evidence of angiogenesis inhibition by $\beta_2$ -glycoprotein I subfractions in the chorioallantoic membrane of chicken embryos. <i>Brazilian Journal of Medical and Biological Research</i> , 2021, 54, e10291.	1.5	1
37	Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100134.	4.0	21
38	Effects of anti-beta 2 glycoprotein 1 antibodies and its association with pregnancy-related morbidity in antiphospholipid syndrome. <i>American Journal of Reproductive Immunology</i> , 2022, 87, e13509.	1.2	9
39	Response to: Correspondence on Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients™ by Liu. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e180-e180.	0.9	0

#	ARTICLE	IF	CITATIONS
40	Antiphospholipid Antibodies From Women With Pregnancy Morbidity and Vascular Thrombosis Induce Endothelial Mitochondrial Dysfunction, mTOR Activation, and Autophagy. <i>Frontiers in Physiology</i> , 2021, 12, 706743.	2.8	11
41	Differences in Endothelial Activation and Dysfunction Induced by Antiphospholipid Antibodies Among Groups of Patients With Thrombotic, Refractory, and Non-refractory Antiphospholipid Syndrome. <i>Frontiers in Physiology</i> , 2021, 12, 764702.	2.8	8
42	Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances. <i>Journal of Clinical Medicine</i> , 2022, 11, 2164.	2.4	18
44	Solid Phase Assays for Antiphospholipid Antibodies. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 661-671.	2.7	11
45	Antiphospholipid syndrome and recurrent pregnancy losses. , 2022, , 121-136.		0
46	Antibodies to domain I $\beta$ 2-glycoprotein 1 in patients with antiphospholipid syndrome and systemic lupus erythematosus. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 353-359.	1.0	1
47	Frequency of positive antiphospholipid antibodies in pregnant women with SARS-CoV-2 infection and impact on pregnancy outcome: A single-center prospective study on 151 pregnancies. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
48	How we treat clinical dilemmas in antiphospholipid syndrome: A case-based approach. <i>European Journal of Internal Medicine</i> , 2022, , .	2.2	0
49	Differences in Antiphospholipid Antibody Profile between Patients with Obstetric and Thrombotic Antiphospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12819.	4.1	4
50	Evolution of Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 295-304.	2.7	4
51	Antiphospholipid antibody-mediated NK cell cytotoxicity. <i>Journal of Reproductive Immunology</i> , 2023, 155, 103791.	1.9	3
52	High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
53	Laboratory Testing for Non-criteria Antiphospholipid Antibodies: Antibodies Toward the Domain I of Beta2-Glycoprotein I (aDI). <i>Methods in Molecular Biology</i> , 2023, , 329-340.	0.9	3
55	Effect of COVID-19 inactivated vaccine on peripheral blood anti- $\beta$ 2-GPI antibody and outcomes in vitro fertilization-embryo transplantation. <i>International Immunopharmacology</i> , 2023, 122, 110596.	3.8	1
56	Anti- $\beta$ 2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China. <i>Lupus Science and Medicine</i> , 2023, 10, e000924.	2.7	0
57	Pursuing appropriateness in antiphospholipid antibodies testing: Feasibility study with a reflex test approach for anti- $\beta$ 2GPI I domain. <i>Autoimmunity Reviews</i> , 2023, 22, 103454.	5.8	0
58	Antibodies to Domain I $\beta$ 2-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus. <i>Doklady Biochemistry and Biophysics</i> , 2023, 511, 219-226.	0.9	0
59	16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome laboratory diagnostics and trends. <i>Lupus</i> , 2023, 32, 1625-1636.	1.6	1

#	ARTICLE	IF	CITATIONS
60	Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones?. <i>Rheumatology</i> , 2024, 63, S14-S113.	1.9	2